European regulators have expanded the scope of Alunbrig (brigatinib) to include its use as a monotherapy for the treatment of adults with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) in the first-line setting.
The approval is based on results from the Phase III ALTA-1L trial, which showed that the drug demonstrated superiority in this treatment setting compared to crizotinib with significant anti-tumor activity observed in patients with baseline brain metastases.
Read more: http://www.pharmatimes.com/news/expanded_eu_approval_for_takedas_alunbrig_1337936